CR20240473A - Anticuerpo que se une a vegf-a e il6 y métodos de uso - Google Patents

Anticuerpo que se une a vegf-a e il6 y métodos de uso

Info

Publication number
CR20240473A
CR20240473A CR20240473A CR20240473A CR20240473A CR 20240473 A CR20240473 A CR 20240473A CR 20240473 A CR20240473 A CR 20240473A CR 20240473 A CR20240473 A CR 20240473A CR 20240473 A CR20240473 A CR 20240473A
Authority
CR
Costa Rica
Prior art keywords
vegf
methods
binds
antibody
antibodies
Prior art date
Application number
CR20240473A
Other languages
English (en)
Spanish (es)
Inventor
Roland Beckmann
Kristian Hobolt Jensen
Anastasia Meier
Janina Speck
Sebastian Fenn
Faye Marie Drawnel
Gabriela Widmer
Barbara Marie-Luise Weiser
Davide Bertoldo
Joerg Benz
Daniela Matscheko
Derrick Feenstra
Stefan Frost
Marlon Hinner
Pamela Strassburger
Oliver Ploettner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20240473A publication Critical patent/CR20240473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR20240473A 2022-05-11 2023-05-11 Anticuerpo que se une a vegf-a e il6 y métodos de uso CR20240473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22172759 2022-05-11
PCT/EP2023/062545 WO2023217933A1 (en) 2022-05-11 2023-05-11 Antibody that binds to vegf-a and il6 and methods of use

Publications (1)

Publication Number Publication Date
CR20240473A true CR20240473A (es) 2025-01-06

Family

ID=81603574

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240473A CR20240473A (es) 2022-05-11 2023-05-11 Anticuerpo que se une a vegf-a e il6 y métodos de uso

Country Status (16)

Country Link
US (1) US20250163139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522648A1 (cg-RX-API-DMAC10.html)
JP (2) JP7801491B2 (cg-RX-API-DMAC10.html)
KR (1) KR20250008903A (cg-RX-API-DMAC10.html)
CN (1) CN119173529A (cg-RX-API-DMAC10.html)
AR (1) AR129268A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023267952A1 (cg-RX-API-DMAC10.html)
CA (1) CA3256863A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003373A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015714A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240473A (cg-RX-API-DMAC10.html)
IL (1) IL316326A (cg-RX-API-DMAC10.html)
MX (1) MX2024013703A (cg-RX-API-DMAC10.html)
PE (1) PE20251283A1 (cg-RX-API-DMAC10.html)
TW (1) TW202402810A (cg-RX-API-DMAC10.html)
WO (1) WO2023217933A1 (cg-RX-API-DMAC10.html)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ATE297452T1 (de) 1998-07-23 2005-06-15 Avebe Coop Verkoop Prod Klebemittelzusammensetzung
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
PT2600812T (pt) 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
SG195196A1 (en) 2011-05-27 2013-12-30 Dutalys Dual targeting
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-수용체 기재 친화성 크로마토그래피
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ. ホフマン-ラ ロシュ アーゲー Vegf及びpdgf-bに結合する抗体及び使用方法

Also Published As

Publication number Publication date
JP2026062918A (ja) 2026-04-10
TW202402810A (zh) 2024-01-16
PE20251283A1 (es) 2025-05-14
CA3256863A1 (en) 2023-11-16
CN119173529A (zh) 2024-12-20
CO2024015714A2 (es) 2025-04-16
WO2023217933A1 (en) 2023-11-16
IL316326A (en) 2024-12-01
US20250163139A1 (en) 2025-05-22
EP4522648A1 (en) 2025-03-19
AU2023267952A1 (en) 2024-10-31
CL2024003373A1 (es) 2025-03-14
MX2024013703A (es) 2024-12-06
JP7801491B2 (ja) 2026-01-16
KR20250008903A (ko) 2025-01-16
AR129268A1 (es) 2024-08-07
JP2025521085A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
CO2023004251A2 (es) Anticuerpo que se une a vegf-a y ang2, y métodos de uso
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
MX2020012639A (es) Anticuerpos frente a entpd2, terapias de combinacion y metodos de uso de los anticuerpos y las terapias de combinacion.
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
PE20241754A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
MX2021003608A (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente.
MX2023002374A (es) Anticuerpo biespecifico anti-calr-cd3 mutante escindido y composicion farmaceutica.
CO2022008314A2 (es) Anticuerpos anti–mertk y métodos de uso de los mismos
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso
PE20230306A1 (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
CO2021008755A2 (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
MX2024008495A (es) Anticuerpos anti-cd84 y receptores de antigenos quimericos.
CO2024015714A2 (es) Anticuerpo que se une a vegf-a e il6 y métodos de uso
CO2024017842A2 (es) Anticuerpos anti-bcma
PE20210103A1 (es) Anticuerpo monoclonal de la glucoproteina g del virus de la laringotraqueitis infecciosa aviar y aplicaciones del mismo
MX2025012526A (es) Agentes de anticuerpos anti-trem1, composiciones y usos de estos
CO2025008269A2 (es) Anticuerpos biespecíficos contra cd3 y cd20 caninas
CO2026003714A2 (es) Anticuerpo que se une a c3bbb
AR113334A1 (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso